Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of tepotinib in MET exon 14 skipping or MET-amplified non-small cell lung cancer
CTR20192576Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tepotinib in non-small cell lung cancer (NSCLC), sponsored by Merck KGaA. Started Jul 2020; status: active.
02
Drugs
tepotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20192576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192576.